CG Oncology

CG Oncology(CGON)

IRVINE, CA
Biotechnology
WebsiteLinkedInCareers Page

Focus: Oncolytic Virus

CG Oncology is a life sciences company focused on Oncolytic Virus.

Oncology
Funding Stage
PUBLIC
Open Jobs
0

Pipeline & Clinical Trials

Cretostimogene Grenadenorepvec
Non-Muscle Invasive Bladder Cancer
N/A
Clinical Trials (1)
NCT06443944An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG
N/A
Phase 1
Clinical Trials (1)
NCT04610671Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC
Phase 1
oncolytic adenovirus expressing GMCSF
Bladder Cancer
Phase 2
Clinical Trials (1)
NCT02143804Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer
Phase 2
Cretostimogene Grenadenorepvec
High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 2
Clinical Trials (1)
NCT06567743Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2
Phase 2
Phase 2
Clinical Trials (1)
NCT02365818Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
Phase 2
CG0070 Adenovirus Vector
Transitional Cell Carcinoma
Phase 2/3
Clinical Trials (1)
NCT01438112Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Phase 2/3
Cretostimogene Grenadenorepvec
Non Muscle Invasive Bladder Cancer
Phase 3
Clinical Trials (1)
NCT04452591Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Phase 3
Cretostimogene Grenadenorepvec
Non Muscle Invasive Bladder Cancer
Phase 3
Clinical Trials (1)
NCT06111235A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Phase 3

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 8 clinical trials
SEC Filings: 2 available

Financials (FY2025)

Revenue
$204K0%
R&D Spend
$46M(22427%)0%
Net Income
-$49M
Cash
$257M
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles